Vyloy® (zolbetuximab-clzb)
for Gastric Cancer Stomach Cancer

Vyloy (zolbetuximab) is a new cancer treatment used for gastric cancer and gastroesophageal junction (GEJ) cancer. It targets the Claudin 18.2 protein on cancer cells, helping to kill the cancer cells and slow tumor growth. Vyloy is FDA-approved as the first-line treatment for claudin 18.2-positive, HER2-negative gastric and GEJ cancer that has spread (metastasized) or cannot be removed by surgery (unresectable).

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Gastric Cancer - Stomach Cancer